Publications by authors named "Q Richier"
Background: Despite vaccination, patients receiving anti-CD20 monoclonal antibodies (mAbs) for multiple sclerosis (MS) or neuromyelitis optica spectrum disorders (NMOSD) have an increased risk of developing severe or protracted COVID-19. The aim of this study was to describe the effect of COVID-19 convalescent plasma (CCP) in patients with MS or NMOSD exposed to anti-CD20 and infected by SARS-CoV-2.
Methods: This French national, retrospective cohort study was conducted between November 2020 and June 2023.
Background: Receiving gifts from patients could generate an ethical dilemma for physicians and refusing a present may be perceived as an offence.
Objective: To differentiate the particular physician characteristics that are associated with receiving gifts from outpatients. To propose a strategy to avoid gifts and thus ethical dilemma.
Article Synopsis
- The study aimed to determine the prevalence and incidence of systemic sclerosis (SSc) on Reunion Island, focusing on its multi-ethnic population and possible environmental and genetic influences.
- Researchers reviewed SSc cases from 2005 to 2021, classifying patients into subsets based on skin conditions and assessing their ethnicity and skin type.
- The findings showed a prevalence of 30.9 cases per 100,000 in 2021 and an annual incidence of 2.13 per 100,000, with results indicating that darker skin types often had pulmonary issues, while lighter skin types experienced more severe gastrointestinal problems.
Convalescent Plasma Therapy in Immunocompromised Patients Infected With the BA.1 or BA.2 Omicron SARS-CoV-2.
Influenza Other Respir Viruses
March 2024
The emergence of SARS-CoV-2 Omicron variant has led to a complete reconfiguration of the therapeutic landscape, with all monoclonal antibodies having lost any neutralization activity. We report here a case series of 75 immunocompromised patients infected by the Omicron variant who benefited from COVID-19 convalescent plasma (CCP). At Day 28, the overall survival was 76% (95% CI 67-86) with no significant difference in the clinical outcome between patients with hematological malignancies, solid organ transplantation or autoimmune diseases.
View Article and Find Full Text PDFWe highlighted in this current paper similar prolonged respiratory presentation with COVID-19 pneumonia in four severely immunocompromised patients currently being treated with anti-CD20 monoclonal antibodies (mAbs), such as ocrelizumab and rituximab, for multiple sclerosis or rheumatoid polyarthritis. Real-time reverse transcription-polymerase chain reaction on a nasopharyngeal swab specimen was negative in all patients. SARS-CoV-2 infection was confirmed from bronchoalveolar lavage fluid.
View Article and Find Full Text PDF